PT - JOURNAL ARTICLE AU - Biswajyoti Borkakoty AU - Mandakini Das Sarmah AU - Chandra Kanta Bhattacharjee AU - Nargis Bali AU - Gayatri Gogoi TI - Antibody response after a single dose of ChAdOx1-nCOV (Covishield™®) vaccine in subjects with prior SARS-CoV2 infection: Is a single dose sufficient? AID - 10.1101/2021.06.15.21258346 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.15.21258346 4099 - http://medrxiv.org/content/early/2021/06/15/2021.06.15.21258346.short 4100 - http://medrxiv.org/content/early/2021/06/15/2021.06.15.21258346.full AB - It is crucial to know whether a single dose of vaccine against SARS-CoV-2 is sufficient to elicit immune response in previously infected people in India. A total of 121 participants (baseline seropositive 46 and seronegative 75) were included to study the immune response to ChAdOx1-nCOV (Covishield) vaccine in previously infected or uninfected people. IgG antibodies were estimated at three different time intervals, i.e. pre-vaccination, 25-35 days post 1st vaccination and 25-35 days post 2nd vaccination. The IgG antibody titre was significantly high among previous seropositive subjects with single dose of vaccine compared to seronegative group with both doses of vaccine respectively (4.59±1.04 vs 3.08±1.22, p-value: <0.0001).In conclusion, a single dose of Covishield™® vaccine might be sufficient to induce an effective immune responsein subjects with prior SARS-CoV2 infection. Stratifying vacinees based on their SARS-CoV2 IgG antibody titre before vaccination would help in meeting the increasing vaccine demand and could be effective to circumvent further wave of the pandemic in India.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPresent study was financially supported by Department of Health Research, New Delhi.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Indian Council of Medical Research- Regional Medical Research Centre North Eastern Region, Dibrugarh's institutional ethics committee approved the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated for the current study are available with the corresponding author.